Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
ADPT Stock Chart & Stats
$14.75
-$0.27(-3.80%)
At close: 4:00 PM EST
$14.75
-$0.27(-3.80%)
Day’s Range― - ―
52-Week Range$5.81 - $20.76
Previous CloseN/A
Volume480.81K
Average Volume (3M)2.01M
Market Cap
$2.84B
Enterprise Value$2.44B
Total Cash (Recent Filing)$212.77M
Total Debt (Recent Filing)$213.64M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Feb 17, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding152,665,190
10 Day Avg. Volume2,558,882
30 Day Avg. Volume2,005,791
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)4.93
P/FCF Ratio-8.93
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue9.66
Enterprise Value/Gross Profit13.45
Enterprise Value/Ebitda-42.73
Forecast
1Y Price Target
$20.17Price Target Upside36.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial HealthThe MRD business segment turned cash flow positive, indicating strong financial health.
Market LeadershipAdaptive is seen as the clear market leader with a lengthy head start versus competition.
Product ExpansionAdaptive's clonoSEQ test can be used for MRD testing in patients with different blood-cancers like multiple myeloma, acute lymphoblastic leukemia, and others.
Bears Say
Competitive ThreatsShares of Adaptive have been weak in recent sessions as fears over Natera’s entrance into the blood-cancer MRD market emerged.
Market CompetitionShares of Adaptive are trading as much as 11% lower following Natera’s purchase of privately held Foresight Diagnostics.
Adaptive Biotechnologies News
ADPT FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was $5.80 and its highest was $20.76 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Adaptive Biotechnologies Corp’s market cap is $2.84B.
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Feb 17, 2026 which is in 71 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on Nov 05, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.147 by $0.207.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -0.18.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 152,665,190 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.147. Following the earnings report the stock price went down -11.541%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Currently, no hedge funds are holding shares in ADPT
Adaptive Biotechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.17 (36.75% Upside)
$20.17 (36.75% Upside)
Hedge Fund Trend
Increased
By 32.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
336.24%
12-Months-Change
Fundamentals
Return on Equity
-37.18%
Trailing 12-Months
Asset Growth
-12.16%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies (ADPT) is a biotechnology company that focuses on utilizing its proprietary immune profiling technology to develop diagnostics and therapeutic solutions. The company operates primarily in the healthcare sector, with a strong emphasis on oncology and infectious diseases. Adaptive's core products include its clonoSEQ assay for measuring and monitoring minimal residual disease in blood cancers and its TCR (T-cell receptor) sequencing technology, which aids in understanding the immune response for various diseases. The company's mission is to harness the power of the adaptive immune system to improve patient outcomes through precision medicine.
ADPT Company Deck
ADPT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in MRD business profitability, improved gross margins, and a solid cash position, with a raised full-year guidance. However, there were challenges in Immune Medicine revenue and uncertainties in regulatory acceptance of MRD as an endpoint.View all ADPT earnings summariesADPT Stock 12 Month Forecast
Average Price Target
$20.17
▲(36.75% Upside)
Technical Analysis
Immunovant
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
Currently, No data available
---